A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.

Trial Profile

A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Aug 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 23 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top